MA33540B1 - Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase - Google Patents

Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase

Info

Publication number
MA33540B1
MA33540B1 MA34654A MA34654A MA33540B1 MA 33540 B1 MA33540 B1 MA 33540B1 MA 34654 A MA34654 A MA 34654A MA 34654 A MA34654 A MA 34654A MA 33540 B1 MA33540 B1 MA 33540B1
Authority
MA
Morocco
Prior art keywords
protein kinase
pyrazine derivatives
kinase modulator
pyridine pyrazine
pyridine
Prior art date
Application number
MA34654A
Other languages
Arabic (ar)
English (en)
Inventor
Paul A Barsanti
Cheng Hu
Jeff Jin
Robert Keyes
Robert Kucejko
Xiaodong Lin
Yue Pan
Keith B Pfister
Martin Sendzik
James Sutton
Lifeng Wan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33540(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33540B1 publication Critical patent/MA33540B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Cette invention concerne un composé représenté par la formule (i) : ainsi que des sels, énantiomères, stéréoisomères, rotamères, tautamères, diastereomères ou racemates pharmaceutiquement acceptables de ce composé. Est également décrit un procédé d traitement d'une maladie ou un état pathologique induit par cdk9.
MA34654A 2009-07-30 2012-02-27 Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase MA33540B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27315409P 2009-07-30 2009-07-30
US35772010P 2010-06-23 2010-06-23
PCT/EP2010/060984 WO2011012661A1 (fr) 2009-07-30 2010-07-28 Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase

Publications (1)

Publication Number Publication Date
MA33540B1 true MA33540B1 (fr) 2012-08-01

Family

ID=42727614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34654A MA33540B1 (fr) 2009-07-30 2012-02-27 Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase

Country Status (31)

Country Link
US (3) US8415381B2 (fr)
EP (1) EP2459535B1 (fr)
JP (2) JP5650735B2 (fr)
KR (1) KR101464052B1 (fr)
CN (1) CN102482218B (fr)
AR (1) AR077505A1 (fr)
AU (1) AU2010277588B2 (fr)
BR (1) BR112012008074A2 (fr)
CA (1) CA2767066A1 (fr)
CL (1) CL2012000092A1 (fr)
CO (1) CO6612188A2 (fr)
CR (1) CR20120051A (fr)
CU (1) CU24091B1 (fr)
DO (1) DOP2012000025A (fr)
EA (1) EA023561B1 (fr)
EC (1) ECSP12011638A (fr)
ES (1) ES2536479T3 (fr)
GE (1) GEP20146101B (fr)
GT (1) GT201200022A (fr)
IL (2) IL217524A0 (fr)
MA (1) MA33540B1 (fr)
MX (1) MX2012001281A (fr)
MY (1) MY183373A (fr)
NI (1) NI201200016A (fr)
NZ (1) NZ597551A (fr)
PE (1) PE20121127A1 (fr)
SG (1) SG177660A1 (fr)
TW (1) TW201107307A (fr)
UY (1) UY32810A (fr)
WO (1) WO2011012661A1 (fr)
ZA (1) ZA201109166B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010211050B2 (en) 2009-02-05 2016-05-12 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
CA2826464C (fr) * 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Derives de triazine disubstitues pharmaceutiquement actifs
JP5947818B2 (ja) 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
EP2699554B1 (fr) * 2011-04-19 2016-11-02 Bayer Intellectual Property GmbH 4-aryl-n-phényl-1,3,5-triazine-2-amines substituées
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2527332A1 (fr) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phényl-1,3,5-triazin-2-amines portant un groupe sulfoximine en tant qu'inhibiteurs de CDK9
EP2562265A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Sensibilité à des inhibiteurs sélectifs de CDK9
EP2561867A1 (fr) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Inhibiteurs de CDK9 pour le traitement du carcinome de la ligne médiane
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
EP2755956B1 (fr) 2011-09-16 2016-05-18 Bayer Intellectual Property GmbH 5-fluoropyrimidines 2,4-disubstituées comme inhibiteurs sélectifs de la cdk9
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
WO2014060375A2 (fr) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft Dérivés 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine contenant un groupe sulfone
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
CA2888383A1 (fr) 2012-10-18 2014-04-24 Bayer Pharma Aktiengesellschaft Derives n-(pyridin-2-yl)pyrimidin-4-amine contenant un groupe sulfone
US9650340B2 (en) 2012-11-15 2017-05-16 Bayer Pharma Aktiengesellschaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
EP3016945B1 (fr) 2013-07-04 2017-05-03 Bayer Pharma Aktiengesellschaft Dérivés de 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine substitués par sulfoximine et leurs utilisation en tant qu'inhibiteurs de kinase cdk9
WO2015136028A1 (fr) 2014-03-13 2015-09-17 Bayer Pharma Aktiengesellschaft Dérivés 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine contenant un groupe sulfone
US9790189B2 (en) 2014-04-01 2017-10-17 Bayer Pharma Aktiengesellschaft Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group
WO2015155197A1 (fr) 2014-04-11 2015-10-15 Bayer Pharma Aktiengesellschaft Nouveaux composés macrocycliques
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CA3000633C (fr) 2014-10-14 2023-10-03 The Regents Of The University Of California Utilisation d'inhibiteurs de cdk9 et d'inhibiteurs de brd4 pour inhiber une inflammation
CA2964696C (fr) 2014-10-16 2022-09-06 Bayer Pharma Aktiengesellschaft Derives de benzofuranyle-pyrimidine fluores contenant un groupe sulfoximine
WO2016059011A1 (fr) 2014-10-16 2016-04-21 Bayer Pharma Aktiengesellschaft Dérivés de benzofuranyle-pyrimidine fluorés contenant un groupe sulfone
WO2016150902A1 (fr) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Utilisation de 4-(4-fluoro-2-méthoxyphényl)-n-{3-[(s-méthylsulfonimidoyl)méthyl]phényl}-1,3,5-triazin-2-amine pour le traitement de cancers gastriques
CA2980507A1 (fr) 2015-03-24 2016-09-29 Public University Corporation Nagoya City University Utilisation de 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine pour traiter des lymphomes
CA2980493A1 (fr) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Utilisation de 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine pour le traitement du myelome multiple
EP3319968A1 (fr) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. N-aminophényl-amides hétérocycliques en tant qu'inhibiteurs de l'histone désacétylase
WO2017007756A1 (fr) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Inhibiteurs hétéro-halogéno d'histone désacétylase
JP6847099B2 (ja) 2015-09-29 2021-03-24 バイエル ファーマ アクチエンゲゼルシャフト 新規な大環状スルホンジイミン化合物
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
CR20180285A (es) * 2015-11-26 2018-07-16 Novartis Ag Derivados novedosos de diamino piridina
HUE057849T2 (hu) 2017-01-11 2022-06-28 Alkermes Inc Hiszton deacetiláz biciklusos gátlói
EP3601236A1 (fr) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Nouveaux composés macrocycliques inhibiteurs de ptefb
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
LT3664802T (lt) 2017-08-07 2022-06-27 Alkermes, Inc. Bicikliniai histonų deacetilazės inhibitoriai
MX2020008447A (es) 2018-02-13 2020-09-28 Bayer Ag Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimi doil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de celulas grandes b.
US11584737B2 (en) 2018-03-29 2023-02-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3790867B1 (fr) 2018-05-11 2024-03-27 Imago Biosciences Inc. Inhibiteurs de kdm1a pour le traitement d'une maladie
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
ES3054109T3 (en) * 2020-05-15 2026-01-29 Algen Biotechnologies Inc Certain chemical compositions and methods of use thereof
WO2022199654A1 (fr) * 2021-03-24 2022-09-29 Chengdu Anticancer Bioscience, Ltd. Composés hétéroaryle-hétéroaryl-o-phényle, compositions et méthodes de traitement de troubles cancéreux
CN114098838B (zh) * 2021-11-12 2022-05-31 北京中研智创新技术研究院有限公司 一种可定向弯曲的用于提取脑组织病变的活检针套件
US20250340527A1 (en) * 2022-05-18 2025-11-06 Trustees Of Tufts College Ripk2 and nod inhibitors
WO2025240628A1 (fr) * 2024-05-15 2025-11-20 Ideaya Biosciences, Inc. Procédés de préparation d'un inhibiteur de pkc
CN119841771B (zh) * 2025-01-08 2026-02-13 华中农业大学 一种猪链球菌丝氨酸蛋白激酶抑制剂的筛选方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4031798A1 (de) 1990-10-08 1992-04-09 Hoechst Ag Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JPH0995489A (ja) * 1995-07-26 1997-04-08 Hokko Chem Ind Co Ltd イソニコチン酸誘導体および農園芸用殺菌剤
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU2001289588A1 (en) 2000-09-25 2002-04-02 Novozymes A/S Phospholipase from zygoascus hellenicus
EP1501514B1 (fr) 2002-05-03 2012-12-19 Exelixis, Inc. Modulateurs de proteine-kinases et leurs methodes d'utilisation
EP2256108B1 (fr) 2002-07-18 2016-03-23 Janssen Pharmaceutica NV Inhibiteurs des kinases a base de triazine substituee
EP1554258A1 (fr) * 2002-08-20 2005-07-20 Neurogen Corporation 2-arylpyrazines substituees en 5 comme modulateurs sur les recepteurs crf
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
JP4867350B2 (ja) 2003-12-19 2012-02-01 宇部興産株式会社 ４−置換−４−シアノテトラヒドロピラン化合物の製法
CA2561895A1 (fr) 2004-04-13 2005-10-27 Icagen, Inc. Pyrimidines polycycliques utilises en tant que modulateurs du canal ionique du potassium
CN101568529A (zh) 2006-12-22 2009-10-28 诺瓦提斯公司 作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
CA2679659C (fr) * 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
US8969386B2 (en) * 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2178537A4 (fr) 2007-07-19 2011-08-17 Merck Sharp & Dohme Dérivés de bêta-carboline en tant que composés antidiabétiques
KR101324804B1 (ko) * 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
JP2011522865A (ja) * 2008-06-13 2011-08-04 ノバルティス アーゲー Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
WO2011026911A1 (fr) * 2009-09-04 2011-03-10 Novartis Ag Bipyridines utilisées dans le traitement des maladies prolifératives
IN2012DN01273A (fr) * 2009-09-04 2015-05-15 Novartis Ag
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途

Also Published As

Publication number Publication date
TW201107307A (en) 2011-03-01
IL217524A0 (en) 2012-02-29
WO2011012661A1 (fr) 2011-02-03
CN102482218A (zh) 2012-05-30
CR20120051A (es) 2012-03-26
JP2015052005A (ja) 2015-03-19
AU2010277588B2 (en) 2012-12-20
MY183373A (en) 2021-02-18
MX2012001281A (es) 2012-03-16
EP2459535B1 (fr) 2015-03-25
GEP20146101B (en) 2014-05-27
UY32810A (es) 2011-02-28
BR112012008074A2 (pt) 2016-03-01
US8778951B2 (en) 2014-07-15
DOP2012000025A (es) 2012-06-15
CU20120015A7 (es) 2012-04-15
KR20120038015A (ko) 2012-04-20
NI201200016A (es) 2012-08-15
US20140288076A1 (en) 2014-09-25
EA023561B1 (ru) 2016-06-30
IL233040A0 (en) 2014-07-31
AU2010277588A1 (en) 2012-01-19
AR077505A1 (es) 2011-08-31
PE20121127A1 (es) 2012-08-16
EP2459535A1 (fr) 2012-06-06
CN102482218B (zh) 2015-01-21
JP2013500311A (ja) 2013-01-07
GT201200022A (es) 2013-12-10
CU24091B1 (es) 2015-04-29
EA201200209A1 (ru) 2012-08-30
US20110028492A1 (en) 2011-02-03
ZA201109166B (en) 2013-05-27
US20130172354A1 (en) 2013-07-04
CA2767066A1 (fr) 2011-02-03
ECSP12011638A (es) 2012-02-29
ES2536479T3 (es) 2015-05-25
KR101464052B1 (ko) 2014-11-20
NZ597551A (en) 2013-10-25
SG177660A1 (en) 2012-03-29
CL2012000092A1 (es) 2012-08-03
JP5650735B2 (ja) 2015-01-07
US8415381B2 (en) 2013-04-09
CO6612188A2 (es) 2013-02-01

Similar Documents

Publication Publication Date Title
MA33540B1 (fr) Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase
EA201070864A1 (ru) Новые гетероциклические соединения
UA99361C2 (uk) ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
NO20091708L (no) Nye kinase inhibitorer
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA37405A1 (fr) Composés hétérocyclyle
TN2014000033A1 (fr) Indazoles
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
EA200802288A1 (ru) Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
EA201001619A1 (ru) Ингибиторы протеинкиназ
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
TW200740760A (en) Malonamide derivatives
EA201390717A1 (ru) 3-(аминоарил)пиридиновые соединения
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
MA35351B1 (fr) Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.